Medicina Nuclear e Tumores Neuroendocrinos

Referências:
1. Klaas P. Koopmans, Oliver N. Neels, Ido P. Kema, Philip H. Elsinga,
Thera P. Links, Elisabeth G.E. de Vries, Pieter L. Jager: Molecular
imaging in neuroendocrine tumors:
Molecular uptake mechanisms and clinical results. Critical Reviews
in Oncology/ Hematology 71 199–213, 2009
2. Pacak K, Linehan WM, Eisenhofer G, et al: Recent advances in
genetics, diagnosis, localization, and treatment of pheochromocytoma.
Ann Intern Med 134:315-329, 2001
3. Pomares FJ, Canas R, Rodriguez JM, et al: Differences between
sporadic and multiple endocrine neoplasia type 2A pheochromocytoma.
Clin Endocrinol 48:195-200, 1998
4. Bombardieri E, Aktolun C, Baum RP, et al: 131I/123I-Metaiodobenzylguanidine
(MIBG) scintigraphy: procedure guidelines for
tumor imaging. Eur J Nucl Med Mol Imaging 30:BP132-BP139,
2003
5. Emilio Bombardieri, Francesco Giammarile , Cumali Aktolun,
Richard P. Baum, Angelika Bischof Delaloye, Lorenzo Maffioli,
Roy Moncayo, Luc Mortelmans, Giovanna Pepe, Sven N. Reske,
Maria R.Castellani, Arturo Chiti: 131I/123I- Metaiodobenzylguanidine
(mIBG) Scintigraphy – Procedures Guidelines For Tumour
Imaging, EANM 2010
6. Troncone L, Rufini V: MIBG in diagnosis of neuroendocrine
tumors, in Ell PJ, Gambhir SS (eds): Nuclear Medicine in Clinical
Diagnosis and Treatment (vol 1). Edinburgh, Churchill Livingstone,
,pp 83-95, 2004
7. Berglund AS, Hulthen UL, Manhem P, et al: Metaiodobenzylguanidine
(MIBG) scintigraphy and computed tomography (CT)
in clinical practice. Primary and secondary evaluation for localization
of pheochromocytomas. J Intern Med 249:247-251, 2001
8. Adams S, Acker P, Lorenz M, et al: Radioisotope-guided surgery
in patients with pheochromocytoma and recurrent medullary
thyroid carcinoma: a comparison of preoperative and intraoperative
tumor localization with histopathologic findings.
Cancer 92:263-270, 2001
9. Boubaker A, Bischof Delaloye A: Nuclear medicine procedures
and neuroblastoma in childhood. Their value in the diagnosis,
staging and assessment of response to therapy. Q J Nucl Med
47:31-40, 2003
10. Rufini V, Salvatori M, Garganese MC, et al: Role of nuclear
medicine in the diagnosis and therapy of medullary thyroid carcinoma.
Rays 25: 273-282, 2000
11. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et
al: Are radiogallium- labelled DOTA-conjugated somatostatin
analogues superior to those labelled with other radiometals? Eur
J Nucl Med Mol Imaging 34(7):982–93, 2007
12. Irene Virgolini, Valentina Ambrosini, Jamshed B. Bomanji,
Stefano Fanti, Michael Gabriel, Nikolaos D. Papathanasiou, Giovanna
Pepe, Wim Oyen, Clemens De Cristoforo, Arturo Chiti:
Procedure Guidelines For PET/CT Tumour Imaging with 68Ga-
DOTAconjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-
NOC, 68Ga-DOTA- TATE. EANM, 2010
13. Reubi JC, Waser B. Concomitant expression of several peptide
receptors in neuroendocrine tumors: molecular basis for in vivo
multireceptor tumour targeting. Eur J Nucl MedMol Imaging 30
(5):781–93, 2003
14. Emilio Bombardieri, Valentina Ambrosini, Cumali Aktolun,
Richard P. Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio,
Lorenzo Maffioli, Luc Mortelmans, Wim Oyen, Giovanna Pepe,
Arturo Chiti: 111In-pentetreotide scintigraphy: procedure guidelines
for tumour imaging, Eur J Nucl Med Mol Imaging 37:1441–
1448, 2010
15. Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM,
Schirmer WJ, et al.
Somatostatin receptor imaging of neuroendocrine tumors with
indium-111 pentetreotide (Octreoscan). Semin Nucl Med 25(3):251–
61, 1995.
16. Dik J. Kwekkeboom, Eric P. Krenning, Klemens Scheidhauer,
Val Lewington, Rachida Lebtahi, Ashley Grossman e Pavel Vitek,
Anders Sundin, Ursula Plöckinger, and the Mallorca Consensus
Conference participants: ENETS Consensus Guidelines for the
Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor
Imaging with 111 In-Pentetreotide. Neuroendocrinology
90:184–189, 2009
17. Z. Win, A. Al-Nahhas, D. Rubello, M. D. Gross: Somatostain
receptor PET imaging with Gallium-68 labeled peptides. Q J Nucl
Med Imaging;51:244-250, 2007
18. M. Ocak, M. Antretter, R. Knopp, F. Kunkel, M. Petrik, N. Bergisadi,
C. Decristoforo:
Full automation of 68Ga labelling of DOTA-peptides including
cation exchange prepurification. Applied Radiation and Isotopes
68, 297-302, 2010
19. Fanti S, et al. Evaluation of unusual neuroendocrine tumours
by means of 68Ga-DOTA- NOC PET. Biomedicine & Pharmacotherapy
62 667-671, 2008
20. Gabriel M, Decristoforo C, Kendler D, et al. 69Ga-DOTATyr3-
Octreotide PET in neuroendocrine tumors: comparison with somatostatin
receptor scintigraphy and CT. J Nucl Med 48: 508–18,
2007
21. Ambrosini V, Tomasetti P, Castellucci P, et al. Comparison between
68Ga-DOTA- NOC and 18F-DOPA PET for the detection of
gastroentero-pancreatic and lung neuro- endocrine tumours. Eur
J Nucl Med Mol Imaging 35:1431–1438, 2008
22. Barbara Gehler, Frank Paulsen, Mehmet Ö Öksüz, Till-
Karsten Hauser, Susanne M Eschmann, Roland Bares, Christina
Pfannenberg, Michael Bamberg, Peter Bartenstein, Claus Belka,
Ute Ganswindt: [68Ga]-DOTATOC-PET/CT for meningioma
IMRT treatment planning Radiation Oncology 4:56, 2009
23. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M,
Botteri E, Baio SM,
Aricò D, Sansovini M, Paganelli G: Peptide receptor radionuclide
therapy with (90)Y- DOTATOC in recurrent meningioma, Eur J
Nucl Med Mol Imaging Sep;36(9):1407-16, 2009